Document is current
Any future updates will be listed below
-
Authors
Han, Gloria T. https://orcid.org/0000-0002-4818-983X
Kala, Shashwat
Naples, Adam
Dawson, Geraldine
Faja, Susan
Shic, Frederick
Webb, Sara Jane
Sugar, Catherine A.
Jeste, Shafali
Kleinhans, Natalia
Chawarska, Katarzyna
Bernier, Raphael
Dziura, James
McPartland, James C.
,
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (T32 GM108554-11)
National Institute of Mental Health (U19 MH108206)
- License Information
-
More Information
Article History
Received: 5 May 2025
Accepted: 19 December 2025
First Online: 14 March 2026
Declarations
:
: The study protocol and applicable consent documents were approved by the Yale University Institutional Review Board (IRB) which served as the Central IRB for the Autism Biomarkers Consortium for Clinical Trials (HIC#1509016477).
: James C. McPartland consults or has consulted with Customer Value Partners, Bridgebio, Determined Health, Apple, Neumarker, and Black Thorn Therapeutics, has received research funding from Janssen Research and Development, serves on the Scientific Advisory Boards of Pastorus and Modern Clinics, and receives royalties from Guilford Press, Lambert, Oxford, and Springer. Frederick Shic is or has been a paid consultant to Definium Therapeutics (formerly MindMed), Janssen, and Roche.
